This article was originally posted on The Limbic Addition of isatuximab to carfilzomib–dexamethasone has been hailed “a new standard of care” for patients with relapsed multiple myeloma. The anti-CD38 monoclonal antibody is already approved in combination with pomalidomide and dexamethasone in many countries for relapsed and refractory multiple myeloma. The phase 3 IKEMA trial comparing...Continue Reading